Trelagliptin

Non Chimik:

(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)methyl)-4-fluorobenzonitrile succinate

Kòd SMILES:

N#CC1=CC=C(F)C=C1CN(C(N2C)=O)C(N3C[C@H](N)CCC3)=CC2=O

Kòd InChi:

InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14( 19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1

InChi kle:

IWYJYHUNXVAVAA-OAHLOKOSA-N

Mot:

Trelagliptin, Trelagliptin succinate, SYR-472, Zafatek, 865759-25-7, 1029877-94-8

Solibilite:Soluble nan DMSO

Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).

Deskripsyon:

Trelagliptin, ke yo rele tou SYR-472, se yon inibitè dipeptidyl peptidase-4 (DPP-4) ke Takeda devlope pou tretman dyabèt tip 2 (T2D). Tretman SYR-472 yon fwa pa semèn te pwodwi amelyorasyon siyifikatif klinik ak estatistik nan kontwòl glisemi nan pasyan ki gen dyabèt tip 2. Li te byen tolere epi li ta ka yon nouvo opsyon tretman pou pasyan ki gen maladi sa a. Trelagliptin (Zafatek(®)) te apwouve nan Japon pou tretman dyabèt tip 2 (T2DM).

Sib: DPP-4